Publications by authors named "B G Goff"
Background: Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our objective was to evaluate contemporary trends in CECs among NCI-sponsored gynecologic cancer clinical trials and protocol adherence to broadened eligibility criteria guidelines as an assessment of equitable enrollment access.
View Article and Find Full Text PDFFunctional Targets for Epstein-Barr Virus BART MicroRNAs in B Cell Lymphomas.
Cancers (Basel)
October 2024
Article Synopsis
- * A meta-analysis of Ago-CLIP datasets from various B cell lymphomas revealed functional interactions between BART miRNAs and over 50 protein-coding transcripts, affecting processes like B cell differentiation, cell cycle regulation, and tumor suppression.
- * Ectopic expression of BART miRNAs in EBV-negative Burkitt lymphomas caused significant transcriptional changes, suggesting their critical role in influencing molecular characteristics of EBV-associated lymphomas.
Article Synopsis
- The French Society of Rheumatology updated its recommendations for managing rheumatoid arthritis (RA) based on the latest EULAR guidelines, involving a wide range of experts and patient representatives.
- The guidelines stress the importance of shared decision-making and comprehensive management for individuals with RA or those at risk, focusing on both drug and non-drug therapies.
- Additional emphasis is on the diagnosis and treatment of RA-related interstitial lung disease (RA-ILD), highlighting the need for collaboration between rheumatologists and pulmonologists for effective management.
Article Synopsis
- Denileukin diftitox (ONTAK) is a fusion protein that can deplete regulatory T cells, which are linked to poor outcomes in ovarian cancer, and this study aimed to assess its safety and effects when given directly into the abdomen of patients with advanced ovarian cancer.
- A phase I trial included 10 patients who received ONTAK at escalating doses, revealing a maximum tolerated dose of 15 μg/kg with mostly mild side effects, though one patient experienced a severe reaction at the highest dose.
- While some patients showed a decrease in CA-125 levels (a marker for ovarian cancer), there were no significant changes in the overall cancer response, although ONTAK successfully reduced regulatory T cells in both blood and